ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2026
Optimized cellular perfusate increases lung viability ex vivo and extends the duration of ex vivo lung perfusion.
Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparing Gas and Inhaled Pharmacologic Interventions During Ex Vivo Lung Perfusion: A Systematic Review.Transplantation direct · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundEx vivo lung perfusion (EVLP) has emerged as a strategy to assess and extend preservation of donor lungs prior to transplantation. However, due to progressive deterioration of the graft, current protocols limit EVLP duration to 10-12 h. We developed an optimized cellular perfusate, DEVOL solution, designed to support multi-day EVLP and evaluated its performance against standard TransMedics OCS perfusate.
methodsPorcine lungs were procured, flushed with OCS solution, and perfused using either STANDARD (n=5) or DEVOL (n=5) perfusate supplemented with washed red blood cells. Physiological parameters, perfusate biomarkers, histology, and transcriptomics were assessed throughout extended perfusion. A lung tissue culture system was employed to investigate procurement flush perfusate reperfusion-related cytokine release.
resultsDEVOL-perfused lungs exhibited increased median perfusion survival time compared with STANDARD (36 vs. 12 h). Improved viability was associated with reduced edema and lower endothelial injury markers (PECAM-1, syndecan-1). DEVOL lungs demonstrated transient early rises in pulmonary vascular resistance and IL-10, as well as sustained elevations in IL-17, without evidence of increased tissue injury. Mathematical simulation and cell culture experiments suggest this phenomenon is due in part to rapid calcium influx into DEVOL-perfused lungs following calcium-free OCS flush during procurement.
conclusionDEVOL perfusate markedly prolongs lung viability during EVLP compared to standard, commercially available perfusate by maintaining oncotic and osmotic balance. Ongoing studies will dissect the contribution of individual DEVOL components to extended perfusion and integrate additional EVLP parameters to elucidate mechanisms underlying late graft failure observed in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.